AI Mental Health Digital Therapeutic MindCure Receives FDA Approval: VR and AI Dialogue Treatment for Anxiety and Depression First to Match Drug-Level Efficacy
Pear Therapeutics' AI mental health digital therapeutic MindCure receives FDA approval, with clinical trials demonstrating its treatment effectiveness for mild-to-moderate anxiety and depression is comparable to first-line medications
AI Mental Health Digital Therapeutic MindCure Receives FDA Approval: VR and AI Dialogue Treatment for Anxiety and Depression First to Match Drug-Level Efficacy
Pear Therapeutics announced on October 8 that its AI mental health digital therapeutic MindCure has received FDA approval. MindCure is a prescription digital therapeutic product that treats mild-to-moderate anxiety and depression through a combination of VR exposure therapy and AI cognitive behavioral therapy (CBT) dialogue.
In a Phase III clinical trial involving 2,400 subjects, MindCure achieved a symptom remission rate of 58% after 8 weeks of treatment, which was not statistically significantly different from the 61% rate of the first-line anti-anxiety medication sertraline. This marks the first time a digital therapeutic has demonstrated efficacy comparable to drugs in a large-scale clinical trial.
MindCure's AI dialogue engine was trained on 2 million hours of real psychological counseling conversations and can identify 23 different cognitive distortion patterns to guide users through cognitive restructuring. The VR module provides graduated exposure therapy, helping users confront and overcome anxiety triggers in a safe virtual environment. The product is priced at $199 per month and requires a doctor's prescription.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.